Company intelligence / Profile preview

SHY Therapeutics

Albany* / Valhalla* [NY Medical College campus], New York, United Statesshytherapeutics.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Their compounds demonstrate significant tumor inhibition with good tolerability in mouse models. The approach targets non-covalent inhibition at the GTP binding site on KRas, differing from existing covalent inhibitors that target specific mutants but lack durable long-term efficacy[1][5].

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small molecule therapeutics
Industry: Biotech

Drug pipeline

1 asset

SHY-ONC6

Partnerships

They collaborate with academic scientists, clinicians, contract research organizations for medicinal chemistry synthesis, pharmacokinetics studies but no major pharma partnerships publicly disclosed yet[1].

Beyond the preview

Go deeper on SHY Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHY Therapeutics.

Explore the full profile